| Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ... Iscience 24 (4), 2021 | 208* | 2021 |
| A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2 KS Kim, K Ejima, S Iwanami, Y Fujita, H Ohashi, Y Koizumi, Y Asai, ... PLoS biology 19 (3), e3001128, 2021 | 165* | 2021 |
| Factors associated with COVID-19 vaccine booster hesitancy: a retrospective cohort study, Fukushima vaccination community survey M Yoshida, Y Kobashi, T Kawamura, Y Shimazu, Y Nishikawa, F Omata, ... Vaccines 10 (4), 515, 2022 | 71 | 2022 |
| Estimation of the incubation period of COVID-19 using viral load data K Ejima, KS Kim, C Ludema, AI Bento, S Iwanami, Y Fujita, H Ohashi, ... Epidemics 35, 100454, 2021 | 66 | 2021 |
| Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study S Iwanami, K Ejima, KS Kim, K Noshita, Y Fujita, T Miyazaki, S Kohno, ... PLoS medicine 18 (7), e1003660, 2021 | 61* | 2021 |
| Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro K Shionoya, M Yamasaki, S Iwanami, Y Ito, S Fukushi, H Ohashi, W Saso, ... Frontiers in Microbiology 12, 651403, 2021 | 34 | 2021 |
| Revisiting the guidelines for ending isolation for COVID-19 patients YD Jeong, K Ejima, KS Kim, S Iwanami, AI Bento, Y Fujita, IH Jung, ... Elife 10, e69340, 2021 | 30 | 2021 |
| Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study K Ejima, KS Kim, AI Bento, S Iwanami, Y Fujita, K Aihara, K Shibuya, ... BMC Infectious Diseases 22 (1), 656, 2022 | 29* | 2022 |
| Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2 H Ohashi, T Hishiki, D Akazawa, KS Kim, J Woo, K Shionoya, ... Antiviral Research 205, 105372, 2022 | 28 | 2022 |
| Designing isolation guidelines for COVID-19 patients with rapid antigen tests YD Jeong, K Ejima, KS Kim, W Joohyeon, S Iwanami, Y Fujita, IH Jung, ... Nature communications 13 (1), 4910, 2022 | 28 | 2022 |
| Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments D Akazawa, H Ohashi, T Hishiki, T Morita, S Iwanami, KS Kim, YD Jeong, ... The Journal of Infectious Diseases 228 (5), 591-603, 2023 | 21* | 2023 |
| Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection KS Kim, S Iwanami, T Oda, Y Fujita, K Kuba, T Miyazaki, K Ejima, S Iwami Life science alliance 4 (10), 2021 | 18 | 2021 |
| A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture S Iwanami, Y Kakizoe, S Morita, T Miura, S Nakaoka, S Iwami Theoretical Biology and Medical Modelling 14, 1-13, 2017 | 18 | 2017 |
| Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir S Torii, KS Kim, J Koseki, R Suzuki, S Iwanami, Y Fujita, YD Jeong, J Ito, ... PLoS Pathogens 19 (3), e1011231, 2023 | 10 | 2023 |
| Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model K Ejima, KS Kim, S Iwanami, Y Fujita, M Li, RS Zoh, K Aihara, T Miyazaki, ... Journal of the Royal Society Interface 18 (177), 20200947, 2021 | 10 | 2021 |
| Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma S Iwanami, K Kitagawa, H Ohashi, Y Asai, K Shionoya, W Saso, ... PLoS biology 18 (7), e3000562, 2020 | 10 | 2020 |
| Quantitative Immunology by Data Analysis Using Mathematical Models S Iwanami, S Iwami Encyclopedia of Bioinformatics and Computational Biology 2, 984-992, 2019 | 10 | 2019 |
| Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24: 102367 H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ... | 9 | 2021 |
| Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021; 24: 102367 H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ... DOI, 2021 | 6 | 2021 |
| Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience, 24 (4), 102367 H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ... | 5 | 2021 |
Shingo IwamiiBLab, Graduate School of Science, Nagoya University, JapanZweryfikowany adres z bio.nagoya-u.ac.jp
